



www.drugcendr.com

### About DrugCendR, Inc.:

#### Addresses a major problem:

Current medications fail to sufficiently penetrate solid tumors.

**Unique Technology:** Increases the effectiveness of most cancer drugs by activating a trans-tissue transport pathway specifically in tumors.

**Strong Validation:** ~100 publications, >10 independent groups, works across a broad range of cancer models.

**Potent and Selective:** Only active in tissues where both primary targets are co-expressed, i.e. solid tumors.

**Simple:** co-administration method, potential to enhance most anti-cancer drugs (small molecules, mAbs, nanoparticles).

**Experienced Team:** World-class management with long biotech / pharma industry experience.

**Strong Commitment:** The founders have personally provided a substantial part of the company funding so far.

**Solid IP position:** Multiple issued and pending patents to 2029+.

**Partners:** Oncology team in place, a Chinese partnership for a follow-up/companion diagnostic compound.

Contact: Dr. Harri Jarvelainen, COO  
(harri.jarvelainen@drugcendr.com)

### DrugCendR Inc. to present at the Biotech Showcase Conferences in San Francisco on January 7 and 10, 2018

Next week is the most important week in healthcare as representatives from hundreds of biopharma companies arrive for meetings in and around San Francisco's Union Square.

During the week, DrugCendR Inc. will present on 2 occasions – first at the China Showcase on Sunday, January 7, as then at the Biotech Showcase, on Wednesday, January 10.

The meeting details are as follows:

#### China Showcase:

Date: Sunday, January 7

Time: 3:15 PM

Room: Parc 55, Level 4, Cyril Magnin I

#### Biotech Showcase:

Date: Wednesday, January 10

Time: 10:15 AM

Room: Hilton San Francisco Union Square Hotel / Franciscan B

As DrugCendR is now preparing to transition from a preclinical to a clinical-stage company, the company will present details on their Phase I –ready lead compound CEND-1 – a highly innovative molecular mimicry agent that is able to activate a drug transport mechanism specifically in solid tumors. To date, there are more than 100 studies using DrugCendR's proprietary technology, providing an unprecedented amount of preclinical validation / proof-of-concept. As the therapy progresses to human studies, the hope is that in addition to increasing the efficacies of anti-cancer therapies, this highly tumor-specific approach could be able to decrease the toxicities caused by the anti-cancer agents.

Biotech Showcase™ and China Showcase™ are investor and networking conferences produced by Demy-Colton and EBD Group.

Additional links and information: <https://www.drugcendr.com/>